logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Mankind Pharma Ltd

Mankind Pharma

Large Cap•26,978 Employees•IPO 2023
Current Price
₹2138.90
-69 (-3.13%)Updated
NSE :MANKIND
BSE :543904
Sector :Pharmaceuticals
Today's Range
2128.7
₹2138.90
indicator
2205
52 Week Range
52W Low₹2012.30
52W High₹2716.50
₹2138.90
indicator
Downside6.29%
Upside27.00%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹85,198.83 Cr
Market Cap
Total market value of company
P/E Ratio
49.09
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
6.58
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹42.60
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
6.30%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
16.00%
ROCE
Return on Capital Employed. >15% is good
Net Margin
12.90%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
13.87%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
15.79%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
24.50%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
-17.60%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.59
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹347.39
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
72.70%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Mankind Pharma demonstrates robust quarterly sales growth, with a 24.5% increase, signaling strong demand for its products and effective market penetration strategies, which is a positive indicator for future revenue streams.
  • •The company maintains a substantial promoter holding of 72.7%, reflecting high confidence from its founders in the long-term prospects and stability, potentially reducing risks associated with management shifts.

Weaknesses

5 points
  • •A notable concern is the recent -17.6% decline in quarterly profit variability, suggesting potential challenges in maintaining profit momentum. Investors should carefully analyze the underlying reasons for this downturn.
  • •Mankind Pharma's high price-to-earnings (P/E) ratio of 53.40, which is above many peers, suggests the stock might be overvalued compared to its earnings, warranting caution and thorough valuation analysis.

Opportunities

4 points
  • •Operating in the Pharmaceuticals and Healthcare sectors, Mankind Pharma benefits from long-term industry tailwinds like increasing healthcare expenditure, population growth, and rising demand for quality medicines.
  • •The company's robust quarterly sales growth of 24.5% positions it well to capitalize on expanding market demand and potentially explore new product segments or geographical markets for further growth.

Threats

5 points
  • •The pharmaceutical industry is highly competitive, with numerous established players and new entrants, posing a constant threat to market share and pricing power, potentially impacting Mankind Pharma's margins.
  • •Stringent and evolving regulatory frameworks in the healthcare sector, including drug pricing controls and approval processes, could introduce operational complexities and impact the company's profitability.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹2338.97+₹200.07+9.35%
R3₹2262.67+₹123.77+5.79%
R2₹2233.83+₹94.93+4.44%
R1₹2186.37+₹47.47+2.22%
PIVOT₹2157.5318.630.87%
CURRENT₹2138.90--
S1₹1957.47-₹181.43-8.48%
S2₹2033.77-₹105.13-4.92%
S3₹2081.23-₹57.67-2.70%
S4₹2110.07-₹28.83-1.35%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
8.02L
(13 Mar 2026)
+34.3% vs avg
Delivery %
75.9%
(13 Mar 2026)
+20.2% vs avg
Avg Volume (20D)
5.97L
(13 Feb - 13 Mar)
20-day average
Avg Delivery %
55.8%
(13 Feb - 13 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %

Peer Comparison

Company Name
ABBOTINDIA
Abbott India Ltd
ALKEM
Alkem Laboratories Ltd
AUROPHARMA
Aurobindo Pharma Ltd
CIPLA
Cipla Ltd
DRREDDY
Dr Reddys Laboratories Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
LAURUSLABS
Laurus Labs Ltd
LUPIN
Lupin Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
TORNTPHARM
Torrent Pharmaceuticals Ltd
ZYDUSLIFE
Zydus Lifesciences Ltd

About

MANKIND

Mankind Pharma Ltd

Mankind Pharma is a prominent Indian pharmaceutical and consumer healthcare company established in 1991 and headquartered in New Delhi. Its core business revolves around the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations and consumer healthcare products, primarily within India but with an expanding international presence. The company's pharmaceutical offerings cater to a wide spectrum of therapeutic areas, encompassing acute and chronic conditions.

A significant portion of Mankind Pharma's pharmaceutical portfolio addresses major health concerns such as infections, cardiovascular issues, gastrointestinal problems, diabetes, dermatological conditions, pain management, neurological disorders, and respiratory illnesses. This extensive range reflects a commitment to providing treatments for a broad array of health needs. The company's strength lies in its ability to develop and manufacture pharmaceuticals across various therapeutic classes.

Beyond pharmaceuticals, Mankind Pharma also has a robust consumer healthcare division. This segment focuses on products designed for over-the-counter use and self-care. Key offerings include male condoms under the Manforce brand, pregnancy detection kits (Prega News), emergency contraceptives (Unwanted-72), antacids (Gas-O-Fas), nutritional supplements, and acne treatments (AcneStar). These consumer products demonstrate the company's commitment to addressing a wider range of health and wellness needs for consumers.

Mankind Pharma's business activities extend beyond its core pharmaceutical and consumer healthcare operations. The company is involved in the trade and export of pharmaceutical and healthcare products, indicating a global reach. Furthermore, it engages in the manufacturing of various materials, including packaging materials, bulk drugs, and consumer goods. This diversification also includes ventures into real estate, leasing, hospitality, and IT services, suggesting a broader business strategy beyond healthcare.

In summary, Mankind Pharma's business model is characterized by its diversified portfolio spanning pharmaceuticals for various therapeutic areas, a substantial consumer healthcare division, and additional ventures in related sectors. The company's success stems from its integration of research, development, manufacturing, and marketing capabilities, coupled with its diverse product offerings and strategic diversification into other businesses.

COMPANY FACTS - MANKIND

Registered Address

262, Okhla Industrial Estate, Phase-III

New Delhi

DELHI

IN

Tel: 911147476600

Website:https://www.mankindpharma.com/

Investor Relations:http://www.mankindpharma.com/investors/financial-reports
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 26,978

IPO Date: 09/05/2023

MANAGEMENT - MANKIND

Mr. Ramesh Juneja

Executive Chairman of the Board

Mr. Prateek Dubey

President, Global Chief Human Resource Officer

Mr. Pramod Gokhale

President, Group Chief Information Officer

Mr. Sheetal Arora

Chief Executive Officer, Whole-Time Director

Mr. Rajeev Juneja

Executive Vice Chairman of the Board, Managing Director

Mr. Ashutosh Dhawan

Chief Financial Officer

Mr. Prakash Agarwal

President Strategy

Dr. Birendra Singh

President - Global Quality Head

Mr. Abhay Srivastava

President - Operations

Mr. Farhat Umar

President - Global Human Resources

Mr. Arjun Juneja

Chief Operating Officer

Mr. Atish Majumdar

Senior Vice President - Sales and Marketing

Investor Questions Answered

Mankind Pharma Ltd (MANKIND) Stock FAQs

Get answers to the most common questions about Mankind Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Mankind Pharma Ltd (MANKIND) is ₹2,138.9. Today, the stock has declined by ₹69.00 (3.13%), trading in a range of ₹2,128.7 to ₹2,205. The stock opened at ₹2,200 with a trading volume of 8,01,859 shares.
Mankind Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹85,198.83 crores, P/E ratio of 49.09, ROE of 6.30%, and ROCE of 16.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Mankind Pharma Ltd (MANKIND) is ₹2,716.5, while the 52-week low is ₹2,012.3. Currently trading at ₹2,138.9, the stock is 18.0% away from its 52-week low and 21.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Mankind Pharma Ltd stock at ₹2,138.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 49.09 and P/B ratio of N/A. Today's performance shows a loss of 3.13%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Mankind Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹2,138.9, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Mankind Pharma Ltd's key financial metrics include: P/E Ratio: 49.09, P/B Ratio: N/A, ROE: 6.30%, ROCE: 16.00%, Dividend Yield: 0.00%, EPS: ₹42.60, Book Value: ₹347.39, Debt-to-Equity: 0.59, and Current Ratio: N/A. The company's market cap stands at ₹85,198.83 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Mankind Pharma Ltd stock opened at ₹2,200 and is currently trading at ₹2,138.9, showing a decline of ₹69.00 (3.13%). The intraday high is ₹2,205 and low is ₹2,128.7. The trading volume stands at 8,01,859 shares, indicating moderate market participation today.
Mankind Pharma Ltd has a Price-to-Earnings (P/E) ratio of 49.09, which means investors are willing to pay ₹49.09 for every ₹1 of earnings. With an EPS of ₹42.60, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Mankind Pharma Ltd has a market capitalization of ₹85,198.83 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹2,138.9) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Mankind Pharma Ltd has a book value of ₹347.39 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹2,138.9, which is 515.7% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Mankind Pharma Ltd has a Return on Equity (ROE) of 6.30% and Return on Capital Employed (ROCE) of 16.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Mankind Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Mankind Pharma Ltd has a debt-to-equity ratio of 0.59, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Mankind Pharma Ltd has an Earnings Per Share (EPS) of ₹42.60, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹2,138.9 and P/E ratio of 49.09, investors are paying 49.09 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Mankind Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Mankind Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Mankind Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (49.09), ROE (6.30%), debt-to-equity (0.59), and growth rates. 2) Technical Analysis - Check 52-week range (₹2012.30 - ₹2716.50), moving averages, and chart patterns. 3) Valuation - Compare current price (₹2138.90) with book value (₹347.39) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Mankind Pharma Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹2,138.9 is 213790x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Mankind Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹2012.30 - ₹2716.50). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.59 indicates leverage. 4) Liquidity Risk - Based on trading volume of 8,01,859 shares. 5) Valuation Risk - P/E of 49.09 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Mankind Pharma Ltd operates in the industry with key metrics: P/E ratio of 49.09, ROE of 6.30%, market cap of ₹85,198.83 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.59), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Mankind Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹2,138.9, with a 52-week range of ₹2012.30 to ₹2716.50. Based on fundamentals like P/E (49.09), ROE (6.30%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Mankind Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹2138.90. 2) Fundamental Deterioration - Declining ROE (currently 6.30%), increasing debt (D/E: 0.59), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Mankind Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.